In January, Merck halted work on two Covid vaccine candidates but has pressed on with research into two products to treat the disease, including a pill-based one called molnupiravir, which it has developed with Ridgeback Biotherapeutics.from Healthcare/Biotech-Industry-Economic Times https://ift.tt/30m9n2w
via IFTTT
0 comments:
Post a Comment